Targeting Kinin Receptors for the Treatment of Neurological Diseases

Author(s): D. Rodi, R. Couture, B. Ongali, M. Simonato

Journal Name: Current Pharmaceutical Design

Volume 11 , Issue 10 , 2005

Become EABM
Become Reviewer
Call for Editor


Kinins (bradykinin, kallidin and their active metabolites) are peptide autacoids with established functions in cardiovascular homeostasis, contraction and relaxation of smooth muscles, inflammation and nociception. They are believed to play a role in disease states like asthma, allergies, rheumatoid arthritis, cancer, diabetes, endotoxic and pancreatic shock, and to contribute to the therapeutic effects of ACE inhibitors in cardiovascular diseases. Although kinins are also neuromediators in the central nervous system, their involvement in neurological diseases has not been intensively investigated thus far. This review analyzes the potential of central kinin receptors as therapeutic targets for neurological disorders. Initial data highlight potential roles for B1 receptor antagonists as antiepileptic agents, and for B2 receptor antagonists (and/or B1 agonists) in the treatment of stroke. Functional B1 receptors located on T-lymphocytes and on the blood brain-barrier are also putative targets for the management of multiple sclerosis. However, successful elucidation of the therapeutic value of these new pharmacological approaches will require refinement of our knowledge on the physiology and cellular localization of central kinin receptors.

Keywords: bradykinin, b1 receptors, b2 receptors, brain, neurological diseases, epilepsy, pain, diabetes, hypertension

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [1313 - 1326]
Pages: 14
DOI: 10.2174/1381612053507422
Price: $65

Article Metrics

PDF: 9